Is Phreesia, Inc. (NYSE:PHR) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Phreesia, Inc. at current levels.
Broken IPO-era darling has finally turned cash-flow positive, and the market is still pricing it like a growth trap.
Where PHR is headed
Phreesia in 2028 looks nothing like the story the market walked away from in 2023. Back then it was a cash-burning intake-tablet company with a bloated sales force and a habit of missing its own targets. Today it sits on $56M of free cash flow, mid-teens revenue growth, and a life sciences advertising business (Phreesia Life Sciences) that has become the highest-margin ad channel in healthcare that most portfolio managers have never heard of. Pharma marketers can reach a diagnosed, name-matched patient sitting in a waiting room seconds before they see their doctor. That is the most valuable ad inventory in any industry, and Phreesia owns it.
Read the full Compass Direction on PHR
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $10.66).
See the full PHR analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Phreesia, Inc. (NYSE:PHR) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Phreesia, Inc. at current levels. Broken IPO-era darling has finally turned cash-flow positive, and the market is still pricing it like a growth trap.
What is PHR's Compass Score?
Phreesia, Inc. scores 45/100 on Alexandria's Compass, placing it in the "Neutral" tier. Scores blend eight factors and update weekly.
What is the price target for PHR?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the PHR page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.